Does a post-merger life sciences company need a fractional Chief Revenue Officer?
A post-merger life sciences company in 2027 almost certainly needs dedicated revenue leadership, but a full-time Chief Revenue Officer is often premature. The merger creates a tangled mess of overlapping sales territories, incompatible CRM data, conflicting compensation plans, and two cultures that don't trust each other. A fractional CRO brings the exact playbook for untangling that mess without the long-term commitment or the politics of an internal hire. If your combined company has between $10M and $50M in revenue and you're trying to hit a unified number within 12–18 months, a fractional CRO is the most cost-effective bet.
CRO Businesses Near You
From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.
For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.
Why Post-Merger Life Sciences Is Different from Other Industries
Life sciences companies - biotech, diagnostics, medical devices, CDMOs - have revenue models that are nothing like SaaS. You're dealing with long sales cycles tied to clinical milestones, regulatory approvals, and procurement processes at hospitals or large pharma buyers. Post-merger, the complexity multiplies because each legacy company may sell to different buyer personas (research labs vs. hospital administrators vs. distributors) with completely different pricing models (subscription, per-test, per-patient, or capital equipment).
A fractional CRO who has only worked in SaaS will struggle here. You need someone who understands the specific revenue rhythms of life sciences: how to align sales territories around therapeutic areas, how to compensate reps for long-cycle deals without burning them out, and how to merge two CRM systems where one tracks "accounts" and the other tracks "sites." The best fractional CROs for this space have held VP or CRO roles at life sciences companies themselves, not just adjacent industries.
The Core Problem: Two Revenue Engines That Don't Talk to Each Other
After a merger, you don't have one revenue team - you have two that are suspicious of each other. Sales reps from Company A don't trust the quotas set by Company B's management. Marketing from Company B has never coordinated with Company A's field team. The compensation plans are so different that one team earns commission on bookings while the other earns it on cash collection.
A fractional CRO's primary job in 2027 is integration, not growth. The growth will come after the integration is stable. That means:
- Harmonizing compensation plans without causing a mass exodus of top reps from either side.
- Cleaning up the CRM (Salesforce or HubSpot) so that pipeline reporting actually reflects reality, not two sets of manual spreadsheets.
- Defining a single go-to-market motion that doesn't confuse buyers with two different product catalogs and pricing sheets.
- Setting a combined revenue target that the board believes in and the teams can actually hit.
This work is messy, political, and requires someone who can tell both legacy CEOs "no" without getting fired. A fractional CRO has the advantage of being an outsider who can make unpopular calls and leave when the integration is done.
When a Full-Time CRO Makes More Sense
There are situations where a fractional CRO is the wrong answer. If your post-merger company is above $75M in revenue and has multiple product lines selling to different buyer types (e.g., instruments, consumables, and services), you likely need a full-time CRO who can build a permanent revenue organization. A fractional leader can't be present for the day-to-day coaching, hiring, and deal escalation that a business of that scale requires.
Also, if the merger was driven by a private equity firm with a 3–5 year hold period, the PE firm may mandate a full-time CRO as part of their operating model. Fractional leaders are sometimes seen as too temporary for PE-backed platforms, though that bias is fading as more PE firms see the value of flexible executive talent.
The Cost Trade-Off: Fractional vs. Full-Time
Let's be honest about the numbers. A full-time CRO in life sciences (Boston, San Diego, Bay Area) commands a base salary of $250k–$350k, plus a bonus of 50–100% of base, plus meaningful equity. Total cash compensation in year one is easily $400k–$700k. Add recruiting fees (25–30% of first-year comp) and the risk of a bad hire, and you're looking at a $500k+ bet that might fail in 6 months.
A fractional CRO at $12k–$18k per month for 10 days of work costs $144k–$216k per year. No recruiting fees, no severance, no equity dilution. If the integration takes 9 months, you spend $108k–$162k total. The trade-off is that you get 40–60% of a full-time executive's attention, so you can't expect them to manage every deal or attend every team meeting. You hire them for specific outcomes, not for general management.
How to Find a Fractional CRO Who Understands Life Sciences
The best fractional CROs for life sciences are not on generic job boards. They are in specialized networks:
- Pavilion (joinpavilion.com) has a strong community of revenue leaders, many with life sciences backgrounds.
- RevOps Co-op (revopsco-op.com) is excellent for finding operators who have done CRM integrations and compensation alignment.
Look for someone who has worked at companies like Illumina, Thermo Fisher, Danaher, or large biotechs - not because those names guarantee success, but because they indicate familiarity with the specific revenue mechanics of life sciences. Also, prioritize candidates who have done at least two post-merger integrations in the last five years. The first integration is a learning experience; the second and third are where the efficiency lives.
FAQ
What is the typical engagement length for a fractional CRO in a post-merger life sciences company? Most engagements run 6 to 12 months. The first 3 months focus on assessment and quick wins (comp alignment, CRM cleanup, pipeline hygiene). The next 3–9 months focus on building a unified go-to-market motion and hitting the first combined revenue target. Extensions are common if the integration is complex or if the company decides to keep fractional leadership longer.
Can a fractional CRO work remotely for a life sciences company? Yes, and most do. Life sciences sales teams are already distributed across territories, so remote leadership is normal. However, you should expect the fractional CRO to travel for key meetings: board presentations, quarterly business reviews, and the first joint sales kickoff. Budget for 1–2 trips per month if the CRO is not local.
Will a fractional CRO report to the CEO or the board? Typically the CEO, but in PE-backed companies, the fractional CRO may also report to the operating partner. The key is to define a clear decision-making scope upfront. The fractional CRO should have authority over sales process, compensation design, and CRM administration, but not over product roadmap or pricing strategy (unless explicitly delegated).
How do we avoid the fractional CRO becoming a bottleneck? Set clear boundaries on availability. A 10-day-per-month engagement means the CRO is not your daily manager. You need to empower your existing sales leadership (VPs, directors) to handle day-to-day operations. The fractional CRO should focus on the integration plan, executive alignment, and key decisions, not on reviewing every deal or attending every forecast call.
Related on PULSE
- [Does a post-merger life sciences company need a fractional CRO in 2027?](/knowledge/tl11855)
- [Does a PE-backed martech company need a fractional CRO in 2027?](/knowledge/tl13255)
- [Should I hire a fractional CRO in Bethany Beach in 2027?](/knowledge/tl20031)
- [Does a bootstrapped edtech company need a fractional Chief Revenue Officer in 2027?](/knowledge/tl16296)
- [Does a founder-led government contracting company need a fractional Chief Revenue Officer in 2027?](/knowledge/tl16576)
- [Should I hire a fractional Chief Revenue Officer in Clinton in 2027?](/knowledge/tl20305)
Sources
- Pavilion - Revenue Leadership Community
- RevOps Co-op - Revenue Operations Network
- Harvard Business Review - Post-Merger Integration
- First Round Review - Executive Hiring and Leadership
- SaaStr - Revenue Leadership and Scaling
- LinkedIn - Fractional Executive Networks
People also search for: fractional chief revenue officer · hire a fractional chief revenue officer · fractional chief revenue officer near me · fractional chief revenue officer cost










